Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RNA learns from antisense.

David R Corey1

  • 1Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75390-9041, USA. david.corey@utsouthwestern.edu

Nature Chemical Biology
|December 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small molecule inhibition of CPSF3 may impact R-loop distribution and abundance.

Bioorganic & medicinal chemistry letters·2026
Same author

Applying Synthetic Nucleic Acid Therapeutics to Gene Activation for Haploinsufficient Diseases.

Nucleic acid therapeutics·2025
Same author

Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression.

Nucleic acids research·2025
Same author

g.nome, A Transparent Bioinformatics Pipeline that Enables Differential Expression and Alternative Splicing Analysis by Non-Computational Biologists.

bioRxiv : the preprint server for biology·2025
Same author

Small molecule inhibition of CPSF3 impacts R-loop distribution and abundance.

bioRxiv : the preprint server for biology·2025
Same author

Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin and silence gene expression.

bioRxiv : the preprint server for biology·2025
Same journal

Cryo-EM sheds light on the mechanism of human telomerase inhibition by BIBR1532.

Nature chemical biology·2026
Same journal

Artificial metalloenzymes in complex biological environments.

Nature chemical biology·2026
Same journal

Allosteric disordering of eIF2B regulates the integrated stress response.

Nature chemical biology·2026
Same journal

A tail of two ligases.

Nature chemical biology·2026
Same journal

Non-canonical cytochrome P450 enzymes expand the diversity of bacterial hemoproteins.

Nature chemical biology·2026
Same journal

Image-guided activation of drugs with electromagnetic radiation.

Nature chemical biology·2026
See all related articles

RNA interference (RNAi) is effective for gene control in cell cultures. Its potential as a therapeutic drug remains uncertain, but insights from antisense oligonucleotide drug development may offer guidance.

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • RNA interference (RNAi) is a powerful biological process for silencing gene expression.
  • RNAi has been widely adopted as a tool in cultured cells for research purposes.
  • The translation of RNAi technology into therapeutic drugs is an active area of investigation.

Purpose of the Study:

  • To evaluate the potential of RNA interference (RNAi) as a therapeutic modality.
  • To explore whether RNAi can be developed into effective drugs.
  • To draw parallels with the development of antisense oligonucleotide drugs.

Main Methods:

  • Review of existing literature on RNA interference.
  • Analysis of gene silencing mechanisms.
  • Comparative study with antisense oligonucleotide drug development pathways.

Related Experiment Videos

Main Results:

  • RNAi is a proven method for gene expression control in vitro.
  • The efficacy and delivery of RNAi therapeutics in vivo are not yet fully established.
  • Antisense oligonucleotide drug development offers a precedent for navigating challenges in nucleic acid-based therapies.

Conclusions:

  • RNAi holds significant promise as a future drug class.
  • Challenges in delivery and stability must be overcome for RNAi drugs.
  • Lessons learned from antisense oligonucleotides can inform the development of RNAi therapeutics.